Compare Gigacloud Technology Inc (GCT) vs Novo Nordisk A/S (NVO) Price & Performance

Gigacloud Technology IncTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs Novo Nordisk A/S — how do they compare? Gigacloud Technology Inc trades at $38.11 (market cap $1.40B), while Novo Nordisk A/S trades at $51.57 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 158.7× Gigacloud Technology Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.

	GCT	NVO
Market Cap	$1.40B	$222.24B
Sector	Technology	Health
52-Week High	$51.80	$71.70
52-Week Low	$20.97	$35.29
Enterprise Value	$1.51B	$241.20B
Dividend Yield	—	3.56%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.

GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.

Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GCT

GigaCloud (GCT) undervalued despite strong growth and solid financials, with $76.50 price target set.Seeking Alpha · 3 days agoBullish View details →

NVO

European Commission approves Wegovy, first oral GLP-1 weight loss pill in EU by Novo Nordisk.Benzinga · 1 day agoBullish Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trendsCustom Market Insights · 2 days agoBullish View details →

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.